 BetterLife Pharma Inc said its wholly owned subsidiary Altum Pharmaceuticals Inc along with Pontificia Universidad Católica de Chile have enrolled the first patient in the Phase 1 portion of the Phase 1-2 randomized placebo-controlled IN2COVID trial in COVID-19 patients. The trial is testing BetterLifes proprietary inhaled interferon alpha-2b product, AP-003. 